Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials
LunAIRo and SynAIRgy are fully enrolled, large Phase 3 clinical trials designed to confirm and extend our understanding of the safety and efficacy of AD109, a combination oral drug targeting the underlying neuromuscular dysfunction contributing to upper airway muscle collapse during sleep in adults with OSA.
Authors
- Patrick J. Strollo (ORCID: https://orcid.org/0000-0002-2065-9641)
- Luigi Taranto‐Montemurro (ORCID: https://orcid.org/0000-0001-7080-0335)
- Ron Farkas
- A. Werner
- Huy Pho
- Sanjay R. Patel (ORCID: https://orcid.org/0000-0002-9142-5172)
- John Yee
- John Cronin
Institutions
- University of Pittsburgh (US)
- Pulmonary and Allergy Associates (US)
- Thermal Technologies (United States) (US)
Publication Details
- Journal
- Contemporary Clinical Trials Communications
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.conctc.2025.101538
- Citations
- 3
- Primary Topic
- Obstructive Sleep Apnea Research
- Type
- article
- Field-Weighted Citation Impact
- 3.49